The SEC repriced the raise, not the reporting: 2026's two moves and your listing plan

The eligibility perimeter is what carries the economics here. Shelf registration paired with an at-the-market programme lets an issuer feed stock into an existing bid over weeks, at prevailing prices, instead of negotiating a block with one buyer who sets the discount. OTC Markets Group's chief executive, writing in Fortune, describes the current route for growth-stage issuers as private placements at steep discounts with significant dilution to existing holders ^[5]. That is the entire argument, and it is a narrow one: the reform lowers the cost of the transaction, not the cost of being a reporting company, which still runs through registration and financial statements as the 1930s framework set it up ^[12].

It is also still a proposal ^[2]. Roughly a fifth of public companies would sit outside the new eligibility even if it is adopted as written ^[4], and perimeters of this kind tend to get drawn tighter between proposal and final rule rather than looser. A company modelling a 2027 raise needs to know which side of the line it lands on and what the raise costs if the line moves.

The January position closes a different door ^[1]. Tokenised distribution changes the settlement layer and the reachable buyer base; it does not change the filing. That is consistent with the 2021 requirement that current issuer information be available before a broker-dealer posts a quote ^[11]: disclosure first, trading second.

Read the venue data with the advocacy in mind. The CEO's stated principle is that disclosure standards rather than balance-sheet size or listing prestige should govern access to public capital ^[15], and OTC Markets operates the markets whose issuers would gain shelf access ^[14]. Its own numbers cut against the growth-company framing. The full-year projection implies second-half volume of about $447 billion, roughly 1.3% below the first half, so the headline figure is a flat-line forecast, not growth ^[8]. And the residual after cross-traded foreign names is around $23 billion of first-half dollar volume, spread across a book of more than 12,000 securities ^[10][6]. An at-the-market programme only works where there is a bid deep enough to absorb the paper. For most of that residual, the volume data does not demonstrate one.

So the planning consequence is unglamorous. The tokenisation question is settled enough to stop treating it as a route around registration, and the offering reform is real enough to price, but only as a contingent alternative to the private placement an issuer would otherwise sign. The number worth calculating now is the spread between the two: the discount and dilution a PIPE would cost against the slower, thinner fills an ATM would deliver in the issuer's actual trading volume. That comparison does not require the rule to be final.